ARG Biotech Participates in China International Import Expo (CIIE 2026)
As part of its strategy to expand international engagement, identify new business and technological opportunities, and strengthen cooperation with leading players in the global pharmaceutical and biotechnology industries, ARG Biotech (Noavaran Zist Gostar Arg Co.) participated in the China International Import Expo (CIIE 2026).
The CIIE is one of China’s major international trade events, bringing together companies, manufacturers, suppliers, investors, and industry professionals from around the world. The exhibition provides a valuable platform for showcasing industrial capabilities, exploring export market opportunities, and establishing new commercial, technological, and strategic partnerships.
ARG Biotech Focuses on Advanced Chromatography and Biopharmaceutical Purification Technologies
One of the key areas of interest for ARG Biotech at CIIE 2026 was exploring the latest technological developments and industrial capabilities in chromatography resins and advanced purification technologies used in biopharmaceutical and biotechnology manufacturing processes.
Chromatography resins are essential materials in the biopharmaceutical industry, playing a critical role in the separation, purification, and enhancement of product purity. These specialized materials are widely used in the downstream processing of high-value biological products, including recombinant proteins, therapeutic peptides, insulin, recombinant vaccines, and plasma-derived medicinal products.
Drawing on its technical expertise and practical experience in the development and manufacturing of chromatography resins, Noavaran Zist Gostar Arg Co. used this international exhibition as an opportunity to explore potential collaborations with global raw material manufacturers, separation technology developers, and companies operating across the biopharmaceutical supply chain.
Key objectives of the company’s participation included identifying reputable international manufacturers and suppliers, exploring business and technological partnerships with Chinese companies, evaluating emerging technologies and innovative products, strengthening the supply chain for specialized raw materials, and assessing opportunities for technology transfer and joint development initiatives.
Furthermore, CIIE 2026 provided an opportunity to gain deeper insights into emerging trends in the biopharmaceutical sector, familiarize with the capabilities of leading global manufacturers, and evaluate new market opportunities for the company’s technology-driven products.
Strengthening International Partnerships and Advancing Purification Technologies
With its strong technical foundation, specialized expertise, and hands-on experience in separation and biopurification technologies, ARG Biotech considers participation in international exhibitions and industry events an integral part of its strategy for market development, enhancing competitiveness, and strengthening scientific and commercial relationships.
Through continued engagement with internationally recognized companies and technology providers, ARG Biotech aims to leverage the opportunities created by such events to improve product quality, optimize manufacturing processes, expand its product portfolio, and enhance the global competitiveness of domestic capabilities in advanced purification technologies.
The company’s participation in CIIE 2026 represents another step toward expanding its international presence and contributing to the development of advanced chromatography and downstream purification solutions for the pharmaceutical and biotechnology industries.

